Analysis of mutations in the FGFR3 gene, using the urine based CertNDxTM Bladder Cancer Assay, detected cancer indicating that the tumor was malignant; which was subsequently confirmed by pathology. The gene discussed is FGFR3; the disease is urinary bladder cancer.